Immunomedics Inc., of Morris Plains, N.J., said it received U.S. Patent No. 6,228,362. It covers a method for targeting boron atoms to tumor cells using a bispecific antibody.
Neugenesis Corp., of San Carlos, Calif., said it received allowance for a U.S. Patent titled ¿Combinatorial Metabolic Libraries.¿ It covers methods for creating panels of cell cultures expressing natural and synthetic variants of multigene metabolic pathways.
Quantum Dot Corp., of Hayward, Calif., said it received U.S. Patent No. 6,207,392 through exclusive license from the University of California. It covers semiconductor nanocrystal probes and their use in biological applications.
Research Corporation Technologies, of Tuscon, Ariz., said it received U.S. Patent No. 6,225,082. It covers a gene expression technology that enhances protein expression in mammalian cells.
Synthetic Blood International Inc., of Costa Mesa, Calif., said the U.S. Patent Office allowed all claims to its new biosensor patent applications. The application covers the use of perfluorocarbon emulsion as an oxygen reservoir in a biosensor.
Syn X Pharma Inc., of Toronto, said it received U.S. Patent No. 6,235,489 titled ¿Method for Diagnosing and Distinguishing Stroke and Diagnostic Devices for use therein.¿ It covers a method for determining whether a patient has had a stroke and, if so, the type of stroke.
Transkaryotic Therapies Inc., of Cambridge, Mass., said it received U.S. Patent No. 6,238,662 titled ¿Synthetic Alpha-L-Iduronidase and Genetic Sequences Encoding Same.¿ It covers methods of treating Hurler syndrome using purified alpha-L-iduronidase from cells transfected with DNA encoding the protein.
Tripos Inc., of St. Louis, said it received U.S. Patent No. 6,240,374. It covers a method for identifying biologically relevant molecules from a virtual library of more than 20 trillion drug-like compounds.